GLP-1 and GIP
Phase 1Small molecule
GLP-1 and GIP is one of 46 small molecule programs targeting Insulin Secretion. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
64 competitors in Insulin Secretion
#DrugCompanyPhaseTrials
1Octreotide
Johnson & JohnsonApproved
Cialis
Eli LillyApproved
Precose
BayerApproved
Farxiga
AstraZenecaApproved
Prograf
VVeloxis Pharmaceuticals
Approved
Decadron
AAspen Global Incorporated
Approved
Cyclosporine a
NovartisApproved
Starlix
NovartisApproved
Galvus
NovartisPhase 3
GLP-1 Receptor Agonist
Boehringer IngelheimApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Insulin Secretion1 trial
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT00992901·160 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GLP-1 and GIP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details